` NWRN (Newron Pharmaceuticals SpA) vs Swiss Market Index Comparison - Alpha Spread

NWRN
vs
Swiss Market Index

Over the past 12 months, NWRN has outperformed Swiss Market Index, delivering a return of 9% compared to the Swiss Market Index's 5% growth.

Stocks Performance
NWRN vs Swiss Market Index

Loading

Performance Gap
NWRN vs Swiss Market Index

Loading
NWRN
Swiss Market Index
Difference

Performance By Year
NWRN vs Swiss Market Index

Loading
NWRN
Swiss Market Index
Add Stock

Competitors Performance
Newron Pharmaceuticals SpA vs Peers

Swiss Market Index
NWRN
LLY
JNJ
NOVO B
ROG
Add Stock

Newron Pharmaceuticals SpA
Glance View

Market Cap
145.7m CHF
Industry
Pharmaceuticals

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

NWRN Intrinsic Value
61.17 CHF
Undervaluation 88%
Intrinsic Value
Price
Back to Top